Journal article icon

Journal article

Monoclonal gammopathy of increasing significance: time to screen?

Abstract:
Monoclonal gammopathy (MG) is a frequently detected clonal B-cell or plasma-cell disorder. Importantly, every multiple myeloma (MM) case is preceded by MG. Although clinical algorithms now allow earlier treatment of patients with biomarkers of malignancy before MM-induced tissue damage (CRAB) occurs, most patients are still diagnosed late. It is important to revisit how MG should be managed in clinical practice and whether screening is required. As the prevalence of MG and other medical co-morbidities both rise with increasing age, the degree of contribution of MG to disease states other than malignant progression is often unclear. This can lead to monitoring lapses and under recognition of the organ dysfunction that can occur with monoclonal gammopathy of clinical significance (MGCS). Therefore, models of progression to MM and/or MGCS require further refinement. While MG is currently detected incidentally, a case for screening has been made with ongoing studies in this area. Screening has the potential benefit of earlier detection and prevention of both MGCS and delayed MM presentations, but important drawbacks include the psychosocial impact on individuals and resource burden on healthcare services. MG terminology should transition alongside our increasing understanding of the condition and genomic characterization that have already begun to revise the MG nomenclature. The biology of MG has been poorly understood and is often inferred from the biology of MM, which is unhelpful. We review the literature and case for MG screening in this paper. In particular, we highlight areas that require focus to establish screening for MG
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.3324/haematol.2022.281802

Authors

More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-0380-7112
More by this author
Role:
Author
ORCID:
0000-0002-1528-7564
More by this author
Role:
Author
ORCID:
0000-0003-4084-8973
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0003-3385-3707


Publisher:
Ferrata Storti Foundation
Journal:
Haematologica More from this journal
Volume:
108
Issue:
6
Pages:
1476-1486
Publication date:
2022-11-10
DOI:
EISSN:
1592-8721
ISSN:
0390-6078


Language:
English
Keywords:
Pubs id:
1304865
Local pid:
pubs:1304865
Source identifiers:
W4308876200
Deposit date:
2026-04-29
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP